Stock Report for Cannabis Science Inc. (CBIS)
  • Penny Stock Spotlight: Fuse Science Inc. (DROP)
  • " />

    Stock Alert for Fibrocell Science Inc. (FCSC)

    Fibrocell Science Inc. (FCSC) is a biotechnology company focused on the development of personalized autologous cell therapies for aesthetic, medical and scientific applications.  The Company’s clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient’s own, or autologous, fibroblast cells produced by its proprietary Fibrocell process. Its clinical development programs encompass both aesthetic and therapeutic indications.

    Share Statistics (22-June-11) FY 












    Symbol FCSC Revenue, $Mn 0.87 0.94 8.0% 0.21 0.21 0.0%
    Current price $1.23 Gross marg. 29.9% 45.7% 52.8% 52.4% 52.4% 0.0%
    52wk Range: $0.39-$1.79 Oper. margin -1235.1% -5023.4%
    Avg Vol (3m): 892,878 Net margin 6973.6% -1375.5% -119.7% -2261.9% -8133.3% 259.6%
    Market Cap. 38.64M
    Shares Outstanding 30.91M EPS, $ -0.89 -0.69 -22.5% -0.30 -0.80 166.7%

    Source:, SEC Filings.

    Investment Highlights

    Shares in the biotechnology company soared more than 54% yesterday on news that U.S. regulators have approved its smile lines wrinkle treatment laViv (azficel-T). FCSC said the patented technology behind laVív is an advanced process that extracts and multiplies a specific kind of a person’s own skin cells (fibroblasts) to create laVív.  The drug is then injected into the patient to improve the appearance of smile lines.  The Company said that in clinical trials, laVív was well tolerated with the majority of adverse events being injection-site reactions that were of mild to moderate intensity and resolved within one week.

    laVív is the first and only personalized aesthetic cell therapy approved by the the U.S. Food and Drug Administration for the improvement of the appearance of moderate to severe nasolabial fold smile lines wrinkles in adults, FCSC stated.

    Dr. Robert A. Weiss, clinical associate professor at Johns Hopkins School of Medicine and director of Maryland Laser Skin & Vein Institute, and an investigator for the laVív clinical trials, commented in the release saying, “The concept of using a patient’s own collagen-making cells is a revolutionary way to help treat nasolabial fold wrinkles and help restore a fresh appearance.  Since this is a biological process that works over time, laVív is able to provide gradual and natural-looking results.”

    As part of the its on-going commitment to patients and to satisfy a post marketing requirement, FCSC will establish a registry of about 2,700 patients to further evaluate the safety of its cell therapy.  laVív will soon be available through trained clinical investigators in select metropolitan areas. As manufacturing capacity is increased and more physicians are trained, the number of cities served will expand as well.

    FCSC shares hit a fresh 52-week high of $1.79 in yesterday’s trading.  The stock is currently trading above its 50-day moving average of $1.19 and above its 200-day moving average of $0.84.  Market capitalization currently stands at $38.64 million and it has 30.91 million outstanding shares.

    Visit FCSC at

    Financial Summary

    FCSC posted revenue of $0.2 million for the first quarter of 2011, unchanged from the first quarter of 2010.

    Net loss for the first quarter of 2011 came in at $17.1 million, up from the prior-year period’s net loss of of $4.7 million.  The Company attributed the increase to the revaluation of the warrant liability and derivative liability associated with the outstanding warrants and preferred stock, respectively, that the Company has issued in its financing transactions.

    Financial Strength (22-June-2011) Company Industry Sector S&P 500
    Quick Ratio (MRQ) 2.85 2.69 2.08 0.71
    Current Ratio (MRQ) 3.07 3.52 2.62 1.03
    LT Debt to Equity (MRQ) 15.22 23.33 136.63
    Total Debt to Equity (MRQ) 19.25 29.50 182.41
    Interest Coverage (TTM) 36.79 5.88 1.61 18.12

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among one polled investment analysts. Against the Fibrocell Science Inc company.

    Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
    Latest 0 1 0 0 0 0
    4 weeks ago 0 1 0 0 0 0
    2 months ago 0 1 0 0 0 0
    3 months ago 0 0 0 0 0 0
    Last year 0 0 0 0 0 0

    The one analyst offering a 12-month price target expects FCSC share pcrie to rise to 3.00 in the next year from the last price of 1.16.


    Consensus Estimates Analysis

    # of Estimates Mean High Low 1 Year Ago
    SALES (in millions)
    Quarter Ending Jun-11 1 280.00 280.00 280.00
    Quarter Ending Sep-11 1 1,260.00 1,260.00 1,260.00
    Year Ending Dec-11 1 4,000.00 4,000.00 4,000.00
    Year Ending Dec-12 1 18,229.00 18,229.00 18,229.00
    EARNINGS (per share)
    Quarter Ending Jun-11 1 -0.08 -0.08 -0.08
    Quarter Ending Sep-11 1 -0.04 -0.04 -0.04
    Year Ending Dec-11 1 -0.31 -0.31 -0.31
    Year Ending Dec-12 1 -0.15 -0.15 -0.15

    Technical Analysis


    FCSC is within its Bollinger Bands. This is a normal condition suggesting that it is neither overbought nor oversold relative to the recent levels.

    FCSC’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    June22-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    Allergan Inc. AGN 82.14 25.03B 22.57 19.56 4.71 4.34
    Integra LifeSciences Holdings Corp. IART 47.75 1.36B 16.08 14.51 1.75 1.64
    Obagi Medical Products Inc. OMPI 9.46 175.33M 12.61 10.17 1.53 1.43
    C.R. Bard Inc. BCR 109.47 9.38B 17.08 15.44 3.20 3.01
    Biotechnology Median 19.23 n/a 10.27 n/a
    Fibrocell Science Inc. FCSC 1.26 38.95M n/a n/a 9.74 2.14

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *